Overview

A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy

Status:
Recruiting

Trial end date:
2022-05-14

Target enrollment:

Participant gender:

Summary

This is a 12 week, 2-arm, blinded, single-site, placebo-controlled Phase II study in subjects with Type II Diabetes and painful peripheral neuropathy.

Phase:

Phase 2

Details

Lead Sponsor:

WinSanTor, Inc

Collaborators:

Eastern Virginia Medical School
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Treatments:

Pharmaceutical Solutions
Pirenzepine